Research Analysts Set Expectations for STERIS Q1 Earnings

STERIS plc (NYSE:STE - Free Report) - Investment analysts at Zacks Research dropped their Q1 2026 earnings per share (EPS) estimates for shares of STERIS in a research note issued to investors on Wednesday, June 4th. Zacks Research analyst R. Department now expects that the medical equipment provider will post earnings per share of $2.29 for the quarter, down from their prior estimate of $2.31. The consensus estimate for STERIS's current full-year earnings is $9.08 per share. Zacks Research also issued estimates for STERIS's Q3 2026 earnings at $2.53 EPS, Q4 2026 earnings at $2.74 EPS, FY2026 earnings at $9.92 EPS, Q1 2027 earnings at $2.58 EPS, Q2 2027 earnings at $2.63 EPS, Q3 2027 earnings at $2.80 EPS, Q4 2027 earnings at $2.67 EPS and FY2027 earnings at $10.68 EPS.

STERIS (NYSE:STE - Get Free Report) last announced its earnings results on Wednesday, May 14th. The medical equipment provider reported $2.74 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.15. STERIS had a return on equity of 13.91% and a net margin of 8.66%. The company had revenue of $1.48 billion for the quarter, compared to the consensus estimate of $1.47 billion. During the same period last year, the business posted $2.58 EPS. The company's revenue was up 5.7% on a year-over-year basis.

Several other brokerages also recently weighed in on STE. Citigroup reaffirmed an "outperform" rating on shares of STERIS in a research report on Friday, May 16th. Needham & Company LLC reiterated a "hold" rating on shares of STERIS in a research note on Monday, April 7th. JMP Securities raised their target price on STERIS from $265.00 to $280.00 and gave the stock a "market outperform" rating in a research report on Friday, May 16th. Stephens restated an "overweight" rating and issued a $250.00 price objective on shares of STERIS in a report on Thursday, May 15th. Finally, Morgan Stanley increased their price objective on STERIS from $240.00 to $260.00 and gave the company an "equal weight" rating in a report on Monday, May 19th. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $263.83.

STERIS Trading Up 0.6%

Shares of STERIS stock traded up $1.46 during mid-day trading on Monday, hitting $242.20. 360,786 shares of the stock were exchanged, compared to its average volume of 549,125. The company has a 50-day simple moving average of $231.51 and a 200 day simple moving average of $222.33. STERIS has a twelve month low of $200.98 and a twelve month high of $252.79. The stock has a market capitalization of $23.83 billion, a price-to-earnings ratio of 51.42 and a beta of 0.94. The company has a current ratio of 2.13, a quick ratio of 1.40 and a debt-to-equity ratio of 0.32.

Institutional Trading of STERIS

A number of hedge funds have recently made changes to their positions in STE. Geneos Wealth Management Inc. lifted its holdings in STERIS by 416.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider's stock valued at $29,000 after purchasing an additional 104 shares during the last quarter. Avalon Trust Co bought a new stake in shares of STERIS during the 4th quarter worth about $30,000. Grove Bank & Trust lifted its holdings in shares of STERIS by 4,733.3% during the first quarter. Grove Bank & Trust now owns 145 shares of the medical equipment provider's stock worth $33,000 after buying an additional 142 shares in the last quarter. Human Investing LLC acquired a new position in shares of STERIS in the fourth quarter valued at about $31,000. Finally, Zions Bancorporation National Association UT bought a new stake in shares of STERIS in the first quarter valued at approximately $37,000. 94.69% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Daniel A. Carestio sold 17,626 shares of the business's stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $242.56, for a total transaction of $4,275,362.56. Following the transaction, the chief executive officer now directly owns 51,385 shares in the company, valued at $12,463,945.60. The trade was a 25.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Cary L. Majors sold 12,828 shares of the firm's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $250.08, for a total transaction of $3,208,026.24. Following the completion of the sale, the senior vice president now owns 11,372 shares of the company's stock, valued at $2,843,909.76. This trade represents a 53.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is owned by corporate insiders.

STERIS Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 26th. Stockholders of record on Tuesday, June 10th will be issued a $0.57 dividend. The ex-dividend date is Tuesday, June 10th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 0.94%. STERIS's payout ratio is presently 36.77%.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.